Stomach Cancer Trial, Recruiting NCT06466902 Sponsor: Azienda Ospedaliero-Universitaria di Parma Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT06466902
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are having minimally invasive surgery (laparoscopic or robotic) aimed at curing stomach cancer (gastric adenocarcinoma)
  • People who are having surgery either as their first treatment or after receiving chemotherapy before surgery
  • People who are having either a full removal of the stomach (total gastrectomy) or a partial removal of the stomach (subtotal gastrectomy)
  • People who are having an extensive removal of nearby lymph nodes during their surgery (known as D2 lymphadenectomy)

Who may not be able to join:

  • People under 18 years of age
  • People whose cancer is located at the junction where the oesophagus meets the stomach (classified as Siewert type I, II, or III)
  • People whose cancer has spread to other parts of the body (metastatic disease)
  • People who are having fewer lymph nodes removed than the D2 standard
  • People who are having open surgery (rather than laparoscopic or robotic)
  • People whose minimally invasive surgery had to be converted to open surgery during the procedure
  • People whose surgery is intended to manage symptoms rather than cure the cancer (palliative gastrectomy)
  • People where cancer cells are found at or near the surgical margins after the operation (R1 or R2 resection)
  • People who are having additional organs removed at the same time, except for the gallbladder
  • People who are having any stomach surgery other than a full or partial stomach removal
  • Cases where more than one reviewer considers a particular lymph node station impossible to assess (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Giorgio Dalmonte, MD, PhD, Azienda Ospedaliero-Universitaria di Parma

Phone: 00390521906343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda Ospedaliero-Universitaria di Parma
Registry
ClinicalTrials.gov
Start date
22 December 2022
Est. completion
1 December 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

PhotoNode Score interobserver agreement

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov